A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer. Baba K, Suzuki N, Imamura CK, Booka E, et al. BMC Cancer 2025;25:675.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Baba K, Suzuki N, Imamura CK, Booka E, et al. A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer. BMC Cancer 2025;25:675.
PMID: 40221699